Niciane (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene expression to suppress the production of inflammatory cytokines, chemokines, and adhesion molecules. This reduces inflammatory cell infiltration and edema, restoring normal nasal airflow with minimal systemic absorption.

The dosing regimen for Niciane is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and specific indication. Healthcare providers set the number of sprays per day and duration of therapy according to approved guidelines.

Safety of Niciane in pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare professional before using the product.

To request Niciane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Niciane (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile due to low systemic bioavailability. Compared with agents like fluticasone or budesonide, mometasone often requires fewer daily sprays to achieve similar symptom control, but choice depends on individual response, tolerability, and prescriber preference.

Store Niciane at room temperature, below 25 °C (77 °F). Keep the spray bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Niciane is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, development of cataracts or glaucoma, nasal septal perforation, and opportunistic fungal infections of the nasal mucosa. Patients should report persistent nosebleeds, visual changes, or signs of infection to their healthcare provider promptly.

Niciane is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery that has not healed, or those for whom systemic corticosteroid exposure is contraindicated.